Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Operating Expenses (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Operating Expenses for 9 consecutive years, with $58.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 27.64% year-over-year to $58.3 million, compared with a TTM value of $191.1 million through Dec 2025, down 4.23%, and an annual FY2025 reading of $191.1 million, down 4.23% over the prior year.
  • Operating Expenses was $58.3 million for Q4 2025 at Puma Biotechnology, up from $44.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $78.0 million in Q1 2021 and bottomed at $42.0 million in Q1 2025.
  • Average Operating Expenses over 5 years is $52.5 million, with a median of $48.9 million recorded in 2021.
  • The sharpest move saw Operating Expenses crashed 40.42% in 2022, then grew 27.64% in 2025.
  • Year by year, Operating Expenses stood at $48.6 million in 2021, then grew by 14.46% to $55.7 million in 2022, then grew by 3.09% to $57.4 million in 2023, then decreased by 20.33% to $45.7 million in 2024, then rose by 27.64% to $58.3 million in 2025.
  • Business Quant data shows Operating Expenses for PBYI at $58.3 million in Q4 2025, $44.9 million in Q3 2025, and $45.8 million in Q2 2025.